Vitamin D: an essential adjuvant therapeutic agent in breast cancer

J Int Med Res. 2022 Jul;50(7):3000605221113800. doi: 10.1177/03000605221113800.

Abstract

Low serum levels of vitamin D have been reported as a risk factor for breast cancer. This narrative review provides an update on the impact of vitamin D on hormone receptors, notably estrogen receptor subunits, and gives insights on possible therapeutic interventions to overcome breast cancer. In addition, evidence that supports the beneficial use of vitamin D as adjuvant treatment of breast cancer is summarized. Vitamin D deficiency is significantly widespread in patients with triple-negative tumors. Several studies have observed a possible modulatory effect of vitamin D or its analogues on the expression of different hormone receptors in breast cancer and increased sensitivity to tamoxifen. Vitamin D possesses anti-inflammatory and immunomodulatory effects in patients with breast cancer, and the mechanism of action of vitamin D in patients with breast cancer is discussed. In conclusion, vitamin D appears to have a beneficial role in the prevention and management of breast cancer, however, large-scale, randomized controlled trials are needed to confirm the effects of vitamin D in breast cancer prevention or treatment.

Keywords: Breast cancer; calcitriol; cancer prevention; estrogen receptor modulation; immunoregulatory activities; pro-inflammatory cytokines.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms* / pathology
  • Female
  • Hormones / therapeutic use
  • Humans
  • Receptors, Estrogen / metabolism
  • Tamoxifen / therapeutic use
  • Vitamin D / therapeutic use

Substances

  • Hormones
  • Receptors, Estrogen
  • Tamoxifen
  • Vitamin D